The content is available as a PDF (1.1 MB).
The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study
Dr Rinkoo Dalan, FRCP
Ms Li Wei Ang, MSc
Dr Wilnard Y T Tan, MBBS
Dr Siew-Wai Fong, PhD
Dr Woo Chiao Tay, MBBS
Dr Yi-Hao Chan, PhD
Laurent Renia, PhD
Lisa F P Ng, PhD
David Chien Lye, FRACP
Daniel E K Chew, FRCP
Dr Barnaby E Young, BM BChir
Corresponding Author : Rinkoo Dalan, Department of Endocrinology, Tan Tock Seng Hospital, Lee Kong Chian School of Medicine, 11 Jalan Tan Tock Seng, Singapore 308433. Email: Rinkoo_dalan@ttsh.com.sg, Phone no: 65-63571000
Roles
Received 2020 Jul 7; Revised 2020 Jul 21; Accepted 2020 Jul 23.
Keywords: hypertension, diabetes, angiotensin-converting enzyme inhibitors (ACE-I), Angiotensin receptor blocker (ARB), dipeptidyl peptidase 4 inhibitors (DPP4i)
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.